ArticleOncotarget2016
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Roy Heusschen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it